| Schedule of Segment Profit or Loss, Including Significant Segment Expenses |
The table below provides a summary of the segment profit or loss, including significant segment expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
June 30, |
|
|
Six Months Ended
June 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
License revenue |
|
$ |
761 |
|
|
$ |
193 |
|
|
$ |
1,224 |
|
|
$ |
1,356 |
|
Research and development expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Claseprubart program-related expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Clinical operation activity costs |
|
|
20,422 |
|
|
|
12,635 |
|
|
|
34,578 |
|
|
|
24,329 |
|
CMC activity costs |
|
|
8,998 |
|
|
|
2,975 |
|
|
|
12,711 |
|
|
|
6,779 |
|
Preclinical study activity costs |
|
|
84 |
|
|
|
795 |
|
|
|
403 |
|
|
|
1,887 |
|
Other |
|
|
— |
|
|
|
50 |
|
|
|
— |
|
|
|
50 |
|
Total claseprubart program-related expenses |
|
|
29,504 |
|
|
|
16,455 |
|
|
|
47,692 |
|
|
|
33,045 |
|
Discovery expenses(1) |
|
|
2,308 |
|
|
|
168 |
|
|
|
3,671 |
|
|
|
1,068 |
|
Personnel and related costs |
|
|
9,254 |
|
|
|
5,962 |
|
|
|
17,888 |
|
|
|
11,809 |
|
Stock-based compensation expense |
|
|
5,643 |
|
|
|
2,459 |
|
|
|
10,491 |
|
|
|
4,934 |
|
Other costs |
|
|
1,977 |
|
|
|
1,207 |
|
|
|
3,472 |
|
|
|
2,398 |
|
Total research and development expenses |
|
|
48,686 |
|
|
|
26,251 |
|
|
|
83,214 |
|
|
|
53,254 |
|
General and administrative expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation expense |
|
|
6,255 |
|
|
|
3,247 |
|
|
|
12,009 |
|
|
|
6,087 |
|
Personnel and related costs |
|
|
4,128 |
|
|
|
2,794 |
|
|
|
8,189 |
|
|
|
5,354 |
|
Other costs |
|
|
3,174 |
|
|
|
2,828 |
|
|
|
5,827 |
|
|
|
4,765 |
|
Total general and administrative expenses |
|
|
13,557 |
|
|
|
8,869 |
|
|
|
26,025 |
|
|
|
16,206 |
|
Other income, net |
|
|
11,267 |
|
|
|
3,298 |
|
|
|
16,966 |
|
|
|
6,964 |
|
Net loss |
|
$ |
(50,215 |
) |
|
$ |
(31,629 |
) |
|
$ |
(91,049 |
) |
|
$ |
(61,140 |
) |
|
|
|
(1) |
|
Discovery expenses include costs associated with DNTH212, DNTH312, and other potential product candidates. |
|